RASi plus carvedilol — Competitive Intelligence Brief

RASi plus carvedilol (RASi plus carvedilol) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ACE inhibitor or ARB combined with non-selective beta-blocker. Area: Cardiovascular.

marketed ACE inhibitor or ARB combined with non-selective beta-blocker Angiotensin II receptor / ACE enzyme; beta-1 and beta-2 adrenergic receptors; alpha-1 adrenergic receptor Cardiovascular Small molecule

Target snapshot

RASi plus carvedilol (RASi plus carvedilol) — Federal University of Minas Gerais. This combination reduces blood pressure and improves heart function by blocking angiotensin II signaling (RASi) while simultaneously reducing heart rate and contractility through beta-blockade (carvedilol).

Comparator set

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
RASi plus carvedilol TARGET	RASi plus carvedilol	Federal University of Minas Gerais	marketed	ACE inhibitor or ARB combined with non-selective beta-blocker	Angiotensin II receptor / ACE enzyme; beta-1 and beta-2 adrenergic receptors; alpha-1 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ACE inhibitor or ARB combined with non-selective beta-blocker class)

1. Federal University of Minas Gerais · 1 drug in this class